Back to Search
Start Over
Developing new PET tracers to image the growth hormone secretagogue receptor 1a (GHS-R1a).
- Source :
-
Nuclear medicine and biology [Nucl Med Biol] 2017 Sep; Vol. 52, pp. 49-56. Date of Electronic Publication: 2017 Jun 10. - Publication Year :
- 2017
-
Abstract
- Introduction: `The growth hormone secretagogue receptor 1a (GHS-R1a) is the orphan G-protein-coupled receptor, and its endogenous ligand is ghrelin. GHS-R1a contributes to regulation of glucose homeostasis, memory and learning, food addiction, and neuroprotection. Several PET tracers for GHS-R1a have been developed, but none have been reported to be clinically applicable to GHS-R1a imaging. In this study, we developed three new PET tracers for GHS-R1a: <superscript>18</superscript> F-labeled 6-(4-chlorophenyl)-3-((1-(2-fluoroethyl)piperidin-3-yl)methyl)-2-(o-tolyl)quinazolin-4(3H)-one (1), <superscript>11</superscript> C-labeled 6-(4-chlorophenyl)-3-((1-(2-methoxyethyl)piperidin-3-yl)methyl)-2-(o-tolyl)quinazolin-4(3H)-one (2), and <superscript>11</superscript> C-labeled (S)-(4-(1H-indole-6-carbonyl)-3-methylpiperazin-1-yl)(4'-methoxy-[1,1'-biphenyl]-4-yl)methanone (3).<br />Methods: [ <superscript>18</superscript> F]1 was synthesized by the <superscript>18</superscript> F-fluoroethylation; [ <superscript>11</superscript> C]2 or [ <superscript>11</superscript> C]3 was synthesized by the <superscript>11</superscript> C-methylation. Biodistribution studies and PET studies were conducted in mice.<br />Results: We successfully radiosynthesized [ <superscript>18</superscript> F]1, [ <superscript>11</superscript> C]2, and [ <superscript>11</superscript> C]3 with appropriate radioactivity for the animal study. In the ex vivo biodistribution study, 60min following injection, the radioactivity level of [ <superscript>18</superscript> F]1 was relatively high in the small intestine, that of [ <superscript>11</superscript> C]2 was high in the liver, and that of [ <superscript>11</superscript> C]3 was high in the pancreas. The radioactivity levels of the three PET tracers were relatively low in the brain. Under pretreatment with YIL781 (a selective and high affinity antagonist for GHS-R1a), the pancreas radioactivity level at 30min following [ <superscript>11</superscript> C]3 injection was significantly reduced to 55% of control, but the radioactivity in the brain was not changed. In the PET study under control conditions, high radioactivity levels in the liver and pancreas were observed following [ <superscript>11</superscript> C]3 injection. With YIL781 pretreatment, the accumulated radioactivity in the pancreas 15-60min after [ <superscript>11</superscript> C]3 injection was significantly decreased to 78% of control.<br />Conclusion: [ <superscript>11</superscript> C]3 exhibited relatively high uptake and in vivo specific binding to GHS-R1a in the mouse pancreas. [ <superscript>11</superscript> C]3 may be a useful PET tracers for in vivo imaging of GHS-R1a in the pancreas.<br /> (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Subjects :
- Animals
Chemistry Techniques, Synthetic
Drug Design
Heterocyclic Compounds, 1-Ring chemistry
Heterocyclic Compounds, 1-Ring pharmacokinetics
Mice
Radioactive Tracers
Radiochemistry
Tissue Distribution
Heterocyclic Compounds, 1-Ring chemical synthesis
Positron-Emission Tomography methods
Receptors, Ghrelin metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1872-9614
- Volume :
- 52
- Database :
- MEDLINE
- Journal :
- Nuclear medicine and biology
- Publication Type :
- Academic Journal
- Accession number :
- 28628775
- Full Text :
- https://doi.org/10.1016/j.nucmedbio.2017.06.002